Versant Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Versant Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-900	Closed	-$115K	–	2861
2026 Q1	$115K	Hold	900	–	–	0.01%	808
2025 Q4	$110K	Hold	900	–	–	0.01%	717
2025 Q3	$90.2K	Hold	900	–	–	0.01%	757
2025 Q2	$74.6K	Sell	900 -900	-50%	-$71.8K	0.01%	792
2025 Q1	$146K	Hold	1,800	–	–	0.02%	506
2024 Q4	$162K	Hold	1,800	–	–	0.03%	212
2024 Q3	$178K	Hold	1,800	–	–	0.04%	165
2024 Q2	$167K	Hold	1,800	–	–	0.04%	155
2024 Q1	$171K	Hold	1,800	–	–	0.05%	137
2023 Q4	$161K	Hold	1,800	–	–	0.05%	141
2023 Q3	$131K	Hold	1,800	–	–	0.04%	151
2023 Q2	$150K	Sell	1,800 -900	-33%	-$75.3K	0.05%	147
2023 Q1	$206K	Hold	2,700	–	–	0.07%	116
2022 Q4	$224K	Hold	2,700	–	–	0.08%	93
2022 Q3	$214K	Hold	2,700	–	–	0.08%	100
2022 Q2	$201K	Hold	2,700	–	–	0.07%	103
2022 Q1	$243K	Buy	+2,700	New	+$249K	0.08%	100

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

LRPA

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Versant Capital Management's XBI Position: Q2 2026 in Review

Versant Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 900 shares — an estimated $115K sold.

Versant Capital Management first reported a position in XBI in Q1 2022 and held it in 17 quarters. The position peaked at $243K in Q1 2022. 225 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Versant Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Versant Capital Management sold 900 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $115K.
Versant Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 17 quarters.
Versant Capital Management's State Street SPDR S&P Biotech ETF position peaked at $243K in Q1 2022.
225 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.